BSE filing, NSE: SOLARA. Summary written from the filing by ALFA Finder's alert engine.
Solara Active Pharma Sciences Ltd: key numbers
- Share price
- ₹653.80
- Market cap
- ₹3,149 Cr
- Revenue (annual)
- ₹1,369 Cr
- Net profit (annual)
- ₹-7.41 Cr
- P/E (TTM)
- 85.3×Sector 46.1×
- Promoter holding
- 41.93%+0.00% QoQ
- FII holding
- 10.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Solara Active Pharma Sciences Ltd
All →Solara Active Pharma Sciences Other Announcement
Solara Active Pharma Sciences Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026. This disclosure details equity ownership across various investor categories.
Solara Active Pharma Sciences Earnings Call Transcript: Key Takeaways
Solara delivered its best profitability in five years despite ongoing Ibuprofen pricing and raw material challenges.
Solara Active Pharma Sciences Investor Presentation: Key Takeaways
Solara's Q2 FY27 delivered record EBITDA and PAT in five years, driven by 33% revenue growth. Base business strength offset Ibuprofen headwinds, which is now nearing breakeven.
Solara Active Pharma Sciences Employee Stock Options
Solara Active Pharma Sciences Limited allotted 8,300 equity shares under its 2018 ESOP plan. The exercise of these options realized Rs. 0.31 Crore for the company.
- Value
- ₹0.31 Cr
Solara Active Pharma Sciences Q2 FY27 Results: Turns Profitable, Net Profit ₹28.5 Cr
Solara Active Pharma Sciences Ltd reported revenue from operations of ₹417.3 Cr (+33.1% YoY) and net profit of ₹28.5 Cr for Q2 FY27.
- Key figure
- Net profit ₹28.5 Cr
Solara Active Pharma Sciences Other Announcement
Solara Active Pharma received an ESG rating of 63 ('Strong' category) from Crisil ESG Ratings for the fiscal year 2026, an upgrade from the prior year.
Other employee stock options announcements
All →Aye Finance Employee Stock Options
Aye Finance's employee welfare trust transferred 89,501 equity shares to grantees on exercising ESOP options. The share capital remains unchanged, so no new issuance occurs.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
OnEMI Technology Solutions Employee Stock Options
OnEMI Technology allotted 69,000 equity shares on exercise of employee stock options under the Kissht ESOP 2022 plan. The shares rank pari passu with existing equity.
Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bandhan Bank Employee Stock Options
Bandhan Bank's board granted 32,98,871 stock options under ESOP Series 1 (Tranche 9) at Rs 151.91 per option. The options vest over four years, with each option convertible into one equity share.
Maxvolt Energy Industries Employee Stock Options
Maxvolt Energy granted 5,01,726 ESOPs to six employees under its MEIL ESOP 2025 scheme at exercise prices of ₹30 and ₹45. Options vest over four years, with exercise windows following vesting.
- Execution
- Vesting over 4 years from grant (25% at 2nd, 25% at 3rd, 50% at 4th anniversary); exercise over 3 years from each vesting date